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The papain-family cathepsins are cysteine pro-
teases that are emerging as promising thera-
peutic targets for a number of human disease
conditions ranging from osteoporosis to can-
cer. Relatively few selective inhibitors for this
family exist, and the in vivo selectivity of most
existing compounds is unclear. We present
here the synthesis of focused libraries of epox-
ysuccinyl-based inhibitors and their screening
in crude tissue extracts. We identified a number
of potent inhibitors that display selectivity for
endogenous cathepsin targets both in vitro
and in vivo. Importantly, the selectivity patterns
observed in crude extracts were generally re-
tained in vivo, as assessed by active-site label-
ing of tissues from treated animals. Overall, this
study identifies several important compound
classes and highlights the use of activity-based
probes to assess pharmacodynamic properties
of small-molecule inhibitors in vivo.
INTRODUCTION
The papain family or clan CA is one of the largest and best-
studied subfamilies of cysteine proteases. A number of
enzymes in this family have been shown to be involved
in physiological processes such as antigen presentation,
bone remodeling, and transcriptional regulation as well
as in important pathological processes such as rheuma-
toid arthritis, Alzheimer’s disease, and cancer (for a review,
see [1]). As a result, a significant effort has been made over
the past 20 years to develop selective inhibitors of mem-
bers of this family in order to gain a better understanding
of the specific roles of these proteases in given disease
states and as potential new therapeutics agents.Chemistry & Biology 14, 49Surprisingly, only a few highly selective inhibitors for any
of the cysteine cathepsins currently exist because devel-
opment is hindered by the high degree of similarity in the
primary S2 substrate-recognition pocket of these prote-
ases. Perhaps the best example of a selective inhibitor is
the compound CA-074, which contains the epoxysuccinyl
reactive group found in the natural product E-64 [2, 3]. This
compound was designed without the benefit of structural
information, but it shows virtually exclusive reactivity with
cathepsin B. The selectivity of CA-074 and related analogs
was later determined to result from efficient hydrogen-
bond interactions between a free carboxylic acid on the
inhibitor and two histidine residues in the so-called oc-
cluding loop structure found only in cathepsin B [4, 5].
This compound and several related classes of com-
pounds have been shown to retain a high degree of selec-
tivity even when used in complex proteomes and intact
cells [6–9].
Developing selective inhibitors of other papain-family
proteases has been more difficult, and few examples of
highly selective inhibitors have been reported [10]. One
CA clan protease, cathepsin K, has recently received sig-
nificant attention due to its role in bone remodeling [11]. In
fact, several major pharmaceutical companies have active
programs to target cathepsin K, and multiple compounds
are currently in human clinical trials for osteoporosis [12].
Interestingly, at least one lead cathepsin K inhibitor in the
clinic, while having selectivity profiles of 1000-fold or bet-
ter over some cathepsin targets, is still a highly potent in-
hibitor of closely related cathepsin off-targets [13]. In ad-
dition, studies of pharmacodynamic properties of these
lead compounds are often difficult to assess due to the
lack of reagents that allow for direct analysis of specificity
in a given tissue or cell population. In general, the process
of drug discovery relies heavily on in vitro testing of lead
compounds against purified enzyme targets to establish
potency and selectivity properties. However, these prop-
erties may not be retained once the compounds are intro-
duced into a whole organism, and actual specificity of9–511, May 2007 ª2007 Elsevier Ltd All rights reserved 499
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Selective Inhibitors of Cysteine Cathepsinsa given compound in a specific cellular location (i.e., in
osteoclasts or tumor cells) is difficult to monitor. Several
recent efforts with activity-based probes (ABPs) in intact
cells and whole animals have demonstrated the value
of these reagents for profiling inhibitor potency and selec-
tivity within the context of a native cellular environment
[14–17].
In this study, we describe the synthesis and screening
of libraries of epoxysuccinyl-based inhibitors and subse-
quent analysis of several classes of novel lead com-
pounds in vivo. We chose to use the epoxysuccinyl scaf-
fold because general inhibitors in this class have been
shown to have activity during multiple stages of tumori-
genesis in mouse models of cancer, while displaying over-
all low toxicity [18], and have also been evaluated as ther-
apeutics in human clinical trials for muscular dystrophy
[19]. In addition, we believe that covalent inhibitors have
the potential to be highly selective in vivo due to the per-
manent nature of the inhibition mechanism that allows
specificity to be controlled by pharmacodynamic proper-
ties that dictate local concentrations of drug. Therefore,
we chose to carry out initial screens in crude extracts to
assess potency and selectivity properties and use this in-
formation to identify lead compounds. A series of opti-
mized inhibitors was tested for standard pharmacokinetic
properties and was also tested for overall in vivo specific-
ity within given tissues by using activity-based protein pro-
filing (ABPP). These studies show that it is possible to rap-
idly identify compounds with a range of selectivity profiles
and potencies, and that these properties could be directly
evaluated in specific cellular locations in vivo.
RESULTS
Design and Synthesis of Libraries of
Epoxysuccinyl-Based Inhibitors
We initially set out to synthesize analogs of the general
clan CA cysteine protease inhibitor E-64. A number of
studies of this inhibitor scaffold have shown that specific-
ity can be modulated by incorporation of structural ele-
ments on both sides of the symmetrical epoxysuccinyl
functional group. Several classes of so-called ‘‘double-
headed’’ epoxides that target CA clan proteases such as
cathepsins B and L have been described [8, 9, 20, 21]. Fur-
thermore, our group recently developed a solid-phase
method that allows for direct synthesis of double-headed
epoxides on resin, thereby allowing for rapid production of
diverse classes of compounds [9]. We therefore initially
designed a set of three sublibraries based on the general
inhibitor JPM-OEt, which contains a tyramine-leucine core
linked to the epoxysuccinate in the 2S,3S conformation
(Scaffolds 1–3; Figure 1A). For these initial libraries, we
used a small set of primary amines to introduce diversity
into the region of the inhibitor shown to bind in the prime
side binding pockets of the target cathepsins [5]. In
addition to the tyrosine-leucine (2S,3S) epoxide library
(Scaffold 3), we explored the contribution of the critical
P2 residue by using a nonnatural p-methyl phenylalanine
(Scaffold 1), shown previously to be an effective structural500 Chemistry & Biology 14, 499–511, May 2007 ª2007 Elsevieelement in this position [22]. Finally, we created a scaffold
in which the core tyrosine-leucine was retained but the
stereochemisty of the epoxide was inverted to the
(2R,3R) configuration (Scaffold 2). Previous work by our
group and others has shown that this change in stereo-
chemistry results in dramatic changes in the overall
potency and specificity of inhibitors [22, 23]. For each
scaffold, we synthesized a set of 17–20 individual com-
pounds by using a subset of the diverse amines shown
in Figure 1.
In addition, we evaluated the importance of the P3
element (R1 diversity site) by synthesizing a library of com-
pounds in which the tyrosine residue of Scaffold 2 was re-
placed with our diverse amines and the R3 position was
held constant as tyramine (Scaffold 4; Figure 1B). This li-
brary of 13 compounds was synthesized by using two
solid-phase synthesis methods recently reported by our
group [24] and was designed to both reduce the peptide
Figure 1. Solid-Phase Synthesis of Focused Epoxysuccinyl-
Inhibitor Libraries
(A) Scaffolds 1, 2, and 3 were synthesized by using a previously re-
ported method and were designed to incorporate diversity into the
P2 and P10 sites as well as to assess the importance of stereochemis-
try of the reactive epoxide group. These libraries contain diverse
amines (structures shown at bottom) in the R3 position linked to scaf-
folds with two different P2 elements (leucine and p-methyl phenylala-
nine) and either R,R or S,S configurations of the epoxide.
(B) Scaffold 4 was synthesized by using two recently described syn-
thesis methods. This library contains diverse amines in the R1 position
with a fixed P10 residue (tyramine). The structure and corresponding
numbering of each amine used in the library synthesis are shown.r Ltd All rights reserved
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Rat Liver Proteomes
(A–C) Individual compounds from (A) Scaffold 1
library, (B) Scaffold 2 library, and (C) Scaffold 3
library were added to crude rat liver extracts
(15 mg total protein) at the final concentration
indicated. After a 30 min incubation, residual
activity of several previously characterized
cysteine cathepsin targets (identified at left of
gel images) was assessed by labeling with
the broad-spectrum papain-family protease
probe 125I-DCG-04. Samples were visualized
by SDS-PAGE, followed by autoradiography.
Values for percent competition relative to con-
trol DMSO-treated samples were determined
for each compound and were plotted by using
a colorimetric format in which the red signal is
strong competition and the blue color is weak
competition.character of the inhibitors and to address the combined
contribution of the P3 element to a compound with fixed
P2 and P10 elements.
Screening of Compound Libraries
in Complex Proteomes
We and others have demonstrated the utility of screening
small-molecule libraries in complex proteomes by using
ABPs as readouts [22, 25, 26]. With this method, com-
pounds are added to a proteome that contains multiple
active targets, whose residual activity after compound in-
cubation can be monitored by using a broad-spectrum ac-
tive-site-directed probe. Thus, it is possible to directly
monitor both the potency and selectivity of a given com-
pound for multiple related targets without the need for sig-
nificant quantities of recombinant enzymes and reporterChemistry & Biology 14,substrates. In addition, results reflect activity against a na-
tive target protease that is present in a more physiologi-
cally relevant environment than a simple buffer system.
We initially screened Scaffold 1–3 libraries by incubating
compounds in total rat liver extracts at set inhibitor con-
centrations for 20 min. Samples were then labeled with
the broad-spectrum ABP 125I-DCG-04, and the residual
activity of cathepsins was determined by SDS-PAGE, fol-
lowed by autoradiography (Figure 2). Values for percent
inhibition relative to the control DMSO-treated sample
were determined by quantification of gel images and
were used to plot specificity profiles for each compound
by using a color format that facilitates visualization of the
data.
The general probe 125I-DCG-04, while capable of label-
ing all of the cysteine cathepsins when used with purified499–511, May 2007 ª2007 Elsevier Ltd All rights reserved 501
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and C in the rat liver extracts. While it is likely that these are
the primary active cathepsins in the extracts, it is not clear
why the probe fails to label cathepsin L, which is ex-
pressed at high levels in the liver. This may be due to
loss of activity of the enzyme upon disruption of the cel-
lular compartments when making tissue extracts or may
be due to the tight regulation of its activity in these tis-
sues. We have previously shown that related compound
125I-JPM-OEt efficiently labels active cathepsin L in intact
cells, but not in extracts prepared from the same cell
population [27]. Regardless of the potential shortcoming,
we proceeded with library screening with a focus on the
primary active cathepsins in the extracts.
Analysis of the initial screening data identified several
interesting specificity trends. The most obvious of these
trends was an overall high degree of selectivity of virtually
all of the double-headed compounds for cathepsin B.
Thus, regardless of the P2 element and the stereochemis-
try of the epoxide, addition of any amine (including simple
ethyl amine) resulted in compounds with specificity for ca-
thepsin B. Only amines 6, 14, 17, and 18 showed any
crossreactivity with cathepsins X, H, and C (Figure 2).
This was in stark contrast to the compounds containing
a free acid or a simple ethyl ester on the epoxide, which
showed broad reactivity toward all the active cathepsins.
It was particularly surprising that the ethyl amide (amine
15) on Scaffold 1 was significantly more cathepsin B
selective than the related compound in which this P10
element was an ethyl ester. This result suggests that back-
bone hydrogen bonding in the S10 region of cathepsin B
may play an important role in dictating overall specificity
and may also help to explain the high degree of selectivity
of cathepsin B inhibitors that contain peptide elements in
this region. Alternatively, the ethyl ester may be processed
to the free acid when added to protein extracts, resulting
in enhanced potency toward all cathepsin targets. We
favor the former explanation, as we see significant differ-
ences in the potency of the free acid and ester forms of
the general inhibitor JPM-OEt, suggesting that the ester
must, to some extent, be retained in extracts.
A second important trend observed in the initial screen-
ing data was the overall change in specificity of com-
pounds when the epoxide stereochemistry was inverted.
In general, all compounds that contained the 2R,3R ste-
reochemistry showed a complete lack of reactivity toward
the two exopeptidases cathepsins H and C. In addition, an
interesting change in specificity was observed for com-
pounds that had a free carboxylic acid and ethyl ester in
the P10 site. These compounds went from being generally
equipotent for cathepsins B and X and also relatively
potent for cathepsins H and C in the context of the
2S,3S epoxide (Figure 2C) to showing cathepsin B selec-
tivity for the ethyl ester and cathepsin X specificity for the
free acid in the context of the 2R,3R epoxide (Figure 2B).
Thus, these results confirm the importance of stereo-
chemistry of the epoxide and provide additional structural
elements that can be exploited to control the specificity of
these compounds.502 Chemistry & Biology 14, 499–511, May 2007 ª2007 ElsevieSynthesis and Pharmacokinetic Evaluation
of a Series of Lead Compounds Designed
Based on Initial Screening Data
We selected a series of compounds for evaluation in fol-
low-on studies by choosing both R2 and R3 elements as
well as epoxide stereochemistries that maximized either
specificity for a given cathepsin target or overall reactiv-
ity toward all cathepsins (Table S1; see the Supplemental
Data available with this article online). We chose several
R2 elements, including the leucine and p-methyl phenyl-
alanine used in the initial library scaffolds, but we also in-
cluded two other nonnatural amino acids (norvaline and
cyclohexylalanine) that had previously been shown to ef-
ficiently bind cathepsin targets [22]. These additional
nonnatural amino acids were included to assess the ef-
fects of nonnatural P2 elements on the pharmacokinetic
(PK) properties of the inhibitors. We selected amines 6,
12, and 17 for use in the R3 position and included a num-
ber of compounds with a free carboxylic acid in this
position. The resulting set of 14 compounds (AMS1–
AMS14) was synthesized and purified for use in in vivo
PK studies. In addition, we included the previously char-
acterized inhibitors JPM-OEt and JPM-acid that were
shown to have anticancer activity in mouse models of
pancreatic cancer ([18] and J.A.J. and M.B., unpublished
data).
We carried out PK studies in normal mice by using in-
travenous (IV) or intraperitoneal (IP) injections or intragas-
tric intubation (PO) of compounds at 50 mg/kg doses
(Figure 3; Table S2). Serum levels of the compounds at
various time points after injection were measured by us-
ing an LC/MS protocol (see Experimental Procedures).
The resulting plots show that all of the compounds are
detected in serum at high concentrations shortly after
IV and IP injections, and that these concentrations drop
rapidly over the next 30 min. While at least one com-
pound was retained at concentrations over 1 mM at 120
min after IV injection, all seemed to show a similar trend
of relatively rapid clearance. In addition, all compounds
showed low or nondetectable levels after PO administra-
tion (see Table S2), suggesting that they were not readily
absorbed by the oral route. This was not surprising since
all of the compounds contained either a free carboxylic
acid or a polar phenol group, thus potentially limiting
their uptake. Past studies with related epoxysuccinyl an-
alogs indicated that conversion of the free acid group on
the epoxide scaffold to an ethyl ester resulted in a pro-
drug that showed improved oral availability and that
was converted to the parent free acid once absorbed
[28]. We therefore synthesized the ethyl ester versions
of AMS1 and AMS7 and analyzed their uptake by PO ad-
ministration compared to JPM-OEt (Figures 3B and 3C;
Table S3). These results show that both compounds
could be detected as their free acid products in serum
after oral administration, and that the observed levels
were similar to JPM-OEt. However, the overall concen-
trations of all of the compounds remained low, suggest-
ing that additional optimization would be required to
improve oral uptake.r Ltd All rights reserved
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Selective Inhibitors of Cysteine CathepsinsFigure 3. In Vivo Pharmacokinetic Properties of Compounds Derived from Initial Screening Data
(A–C) A total of 14 individual compounds (AMS1–AMS14; see Table S1 for structures) were selected based on predicted specificity or general reac-
tivity for the cathepsins in rat liver extracts. Compounds were resynthesized, purified, and used to treat wild-type male nu/nu NCr mice at 50 mg/kg
final concentrations. (A) Compounds were administered by intravenous (IV) and intraperitoneal (IP) injection, and serum levels of compounds were
monitored at various times after injection by using a mass spectrometry-based readout. (B) Serum levels of ethyl ester versions of two of the original
AMS compounds after oral administration (PO) at 50 mg/kg measured as in (A). Note: due to the rapid conversion of these esters to the free carboxylic
acids in mouse serum, levels that were measured and shown here are for the corresponding free acids, and not for the parent ethyl ester pro-drugs. (C)
Measurement of serum levels of the parent JPM-OEt after IV and IP injections as in (A). Oral availability of JPM-OEt determined as in (B).Evaluation of In Vitro and In Vivo Potency
and Selectivity of AMS1, AMS5, and AMS7
The overall potency and selectivity of each of the 14 AMS
compounds were tested in rat liver extracts. Calculation of
IC50 values from competition studies allowed us to priori-
tize compounds and select a set of three compounds with
selectivity for cathepsin X, cathepsin B, or all cathepsins.
The compound AMS1 was selected because it showed
some degree of cathepsin X selectivity, while AMS5 was
highly selective for cathepsin B. AMS7, a close relative
to the parent compound JPM-565, was broadly reactive
for all cathepsins in the lysates (Figure 4A). All three com-
pounds were potent in the nanomolar range and were
comparable in overall potency to the parent JPM-OEt
(Figure 4B).
We next wanted to determine if the overall specificity
profiles that we observed in crude liver extracts could be
retained in vivo. For this study, we treated wild-type
C57BL/6 mice at 13 weeks of age by IP injection withChemistry & Biology 14,each of the compounds at 50 and 100 mg/kg daily for 5
days. At the end of the dosing, samples of tissues from
liver and kidney were collected, and residual cathepsin
activity was measured by in vitro labeling of tissue extracts
with the radiolabeled probe 125I-DCG-04 (Figure 4C). Like
the parent compound JPM-OEt, all three analogs tested
showed overall low acute toxicity, as measured by the
normal appearance of the animals and their general
good health throughout the 5 day course of treatment.
Analysis of residual cathepsin activity in the tissues of
treated mice indicated that all three compounds were
able to gain at least partial access to pools of cathepsins
in the liver and kidney. Not surprisingly, uptake in the liver
was more efficient than in the kidneys, as measured by
more complete inhibition in liver tissues for all compounds
tested. More importantly, the pattern of specificity for
each compound closely matched the patterns observed
in vitro, with AMS1 showing the most effective inhibition
of cathepsin X, AMS5 showing more selective inhibition499–511, May 2007 ª2007 Elsevier Ltd All rights reserved 503
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Selective Inhibitors of Cysteine CathepsinsFigure 4. In Vitro and In Vivo Specificities of Selected AMS Compounds from Scaffolds 1, 2, and 3
(A) Dose-response profiles of AMS1 (Cat B- and X-selective), AMS5 (Cat B-selective), and AMS7 (general) in crude rat liver lysates assessed by
competition for labeling with 125I-DCG-04.
(B) Quantification of IC50 values for AMS1, AMS5, and AMS7 against cathepsins X, B, H, and C based on the dose-response profiles in (A).
(C) In vivo selectivity of AMS1, AMS5, and AMS7 assessed by treatment of normal mice at doses of 50 and 100 mg/kg daily for 5 days. Tissues from
control (DMSO vehicle-treated) and inhibitor-treated mice were collected, homogenized, and labeled with the general probe 125I-DCG-04 to reveal
residual activity.
(D) In vivo activity of AMS1 and AMS5 in RIP1-Tag2 tumors after IP treatment of tumor-bearing mice at 50 mg/kg daily for 5 days. Residual cathepsin
activity in tissues was measured as in (C). Samples from two mice from each compound at the same dose are shown.of cathepsin B, and AMS7 showing general inhibition of all
of the cathepsin targets in both tissues. This result was
particularly interesting because it suggests that even after504 Chemistry & Biology 14, 499–511, May 2007 ª2007 Elsevierprolonged treatment regimens, the fast clearance of the
compounds and the irreversible mechanism of inhibition
may help them to retain target selectivity.Ltd All rights reserved
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Selective Inhibitors of Cysteine CathepsinsFigure 5. Screening of the Scaffold 4 Library and Identification of Optimal R1 Elements
Individual compounds from the Scaffold 4 library containing 13 diverse amines were added to crude rat liver extracts for 30 min at a range of con-
centrations as indicated. Residual activity of cysteine cathepsins was assayed by labeling of the extracts with 125I-DCG-04, followed by analysis by
SDS-PAGE. As in Figure 2, percent competition values were converted to color values and plotted for the series. Note that amine 3 and amine 8 were
the only species that showed significant activity.In addition, we tested the ability of AMS1 and AMS5 to
block activity of cathepsin targets in tumor tissues from
the RIP1-Tag2 transgenic mice used in earlier studies
with the parent JPM-OEt [18]. AMS7 was not tested be-
cause of its close similarity in structure to JPM-OEt, which
has been extensively tested in this model. We carried out
IP injections of tumor-bearing mice at 13 weeks of age for
5 days at the dose of 50 mg/kg as previously described
for the normal controls. Samples of dissected tumors
from two mice treated with each compound were ana-
lyzed by active-site labeling with 125I-DCG-04 (Figure 4D).
These results indicated that, while there was some degree
of variability in both the samples and the controls, both
compounds failed to significantly reduce the activity of
two primary cathepsin activities (cathepsins B and X).
This is likely due to reduced accumulation and poor
uptake for these free acid-containing compounds in tu-
mor tissues.
Evaluation of Scaffold 3 Inhibitors with Variable P3
Elements and Reduced Peptide Character
While we were able to obtain some selectivity for specific
cathepsin targets and this overall specificity was retained
in vivo, the uptake and cell permeability of this first gener-
ation of lead compounds into tumor tissues was low. We
therefore set out to analyze the Scaffold 4 library and de-
termine if we could increase potency as well as cellular up-
take by reducing the number of amide bonds in the com-
pounds. The primary advantage of this scaffold is that it
allows us to replace the amide bond used for resin attach-
ment with simple amines.
We designed the Scaffold 4 library to contain a tyramine
element in the P10 position since we found that this residue
strongly favored binding to cathepsin B (i.e., AMS5).Chemistry & Biology 14,Screening of the library of compounds in rat liver extracts
at a range of concentrations identified several amines that
could be used to generate cathepsin B-selective com-
pounds (Figure 5). Interestingly, the compound made
with amine 6 was nearly identical in structure to AMS5,
but it was a relatively weak, though selective, inhibitor of
cathepsin B. Thus, we lost significant potency by replac-
ing the tyrosine with tyramine, potentially as a result of
loss of hydrogen bonding of the backbone amide in the
active site. However, two amines showed interesting pat-
terns of potency and selectivity. Amine 3, which contained
a pyridine ring, showed potent and selective inhibition of
cathepsin B, while amine 8, which contains a bulky naph-
thyl group, produced a compound with broad reactivity for
all of the cathepsin targets. These two amines were used
to make a class of follow-on lead compounds that also
made use of the information from our earlier screening
efforts with Scaffolds 1–3.
Synthesis and In Vitro and In Vivo Evaluation
of an Advanced Lead Series
As a final step in our medicinal chemistry efforts, we de-
signed a series of four compounds that contained optimal
pharmacophores at each of the R1, R2, and R3 sites,
which made use of the R,R and S,S stereochemistry of
the epoxide (Figure 6A). We designed the compound
AMS17 to be cathepsin B selective by using the pyridyl
ethyl amine (amine 3) in the P3 position, leucine in the
P2 position, and tyramine in the P10 position. AMS28
was designed to target all cathepsins and made use of
the naphthalenemethyl amine in the P3 position to en-
hance potency. In addition, the ethyl ester was chosen
for the P10 site to prevent unwanted specificity toward ca-
thepsin B. We also incorporated the naphthalenemethyl499–511, May 2007 ª2007 Elsevier Ltd All rights reserved 505
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(A) A series of four compounds (AMS17, AMS28, AMS30, and AMS36) that were optimized based on all screening data were selected for further
analysis of potency and selectivity (see chart at top).
(B) In vitro dose response was assessed by treatment of rat liver extracts at a range of concentrations, followed by labeling with 125I-DCG-04. Samples
were analyzed by SDS-PAGE, followed by autoradiography. Data for the parent compound JPM-OEt are included for comparison. IC50 values for
each compound against each of the four cathepsins are shown to the right of the gel images. The control untreated sample used to calculate the
IC50 values is shown at the bottom of the figure.amine into the P3 position of AMS30 and used the R,R
stereochemistry of the epoxide to direct specificity toward
only cathepsins B and X. Finally, we used the naphthale-506 Chemistry & Biology 14, 499–511, May 2007 ª2007 Elsevienemethyl amine P3 in AMS36 and incorporated the non-
natural p-methyl phenylalanine in the P2 position to in-
crease the potency toward cathepsin X.r Ltd All rights reserved
Chemistry & Biology
Selective Inhibitors of Cysteine CathepsinsAnalysis of the in vitro potency and selectivity of AMS17,
AMS28, AMS30, and AMS36 in rat liver extracts indicated
that all of the predicted specificity patterns were obtained
(Figure 6B). In particular, AMS17 was highly specific for
cathepsin B, while AMS36 had some degree of specificity
for cathepsin X. In addition, AMS28 was an extremely po-
tent and broad-spectrum inhibitor that showed enhanced
potency compared to the parent JPM-OEt. Finally, AMS30
was extremely potent and selective for both cathepsin B
and cathepsin X and showed no crossreactivity with
cathepsins H and C even at high concentrations. Thus,
we could achieve enhanced potency and selectivity for
specific cathepsin targets by using optimal specificity
elements from all three variable positions on the inhibitor
scaffold.
Finally, we tested our advanced leads in vivo to deter-
mine if our observed in vitro specificity profiles were re-
tained in various tissues of the RIP1-Tag2 transgenic
mice. As described for our initial lead compounds, each
of the advanced leads (AMS17, AMS28, AMS30, and
AMS36) was IP injected at final concentrations of 50 and
100 mg/kg daily for 5 days. Tissues from liver, kidney,
and tumors were harvested and analyzed by active-site
labeling with 125I-DCG-04 (Figure 7). Unfortunately, the
solubility of AMS36 proved problematic and required the
use of high concentrations of DMSO in the formulation
of the drug. Therefore, we were only able to administer
the drug for a single day due to toxicity to the animals. In
addition, AMS28 showed significant toxicity at both
doses, and, as a result, mice treated at the higher dose
(100 mg/kg/day) had to be sacrificed. These issues with
toxicity and formulation are most likely due to the in-
creased hydrophobicity (formulation) and increased cell
permeability and potency (toxicity) of the advanced lead
series that contain the P3 amines. However, further evalu-
ation of these issues, including lowering the dosage, will
be required.
Regardless of the toxicity and formulation issues, we
were able to harvest tissues from all of the mice and ana-
lyze the potency and selectivity of the compounds. As ex-
pected, AMS28 completely blocked the activity of all ca-
thepsins in all tissues, including the tumors. In addition,
it showed significantly enhanced potency and cell perme-
ability relative to the related compound, AMS7. The ca-
thepsin X-specific inhibitor AMS36 showed broad-spec-
trum inhibition in the liver with some degree of cathepsin
X selectivity in the kidney at the lower dose of 50 mg/kg.
Interestingly, this compound showed cathepsin X selec-
tivity in tumor tissues at both doses tested. AMS30, on
the other hand, showed highly selective cathepsin X and
cathepsin B inhibition in all tissues, likely due to the fact
that it contains the R,R epoxide, which precludes binding
to cathepsins H and C. Surprisingly, we observed an en-
hanced labeling of cathepsin H and C in liver and kidney
tissues relative to the control samples suggesting a poten-
tial upregulation or loss of turnover of these cathepsins as
a result of inhibition of cathepsins B and X. Similar findings
have been reported for other cathepsin targets in other in
vivo models [29]. Finally, the cathepsin B-specific com-Chemistry & Biology 14, 4pound AMS17, like AMS36, seemed to accumulate in liver
and kidney and therefore blocked the activity of all cathep-
sins in those tissues at the higher doses of drug, but re-
tained some degree of selectivity for cathepsin B in tumor
tissues. Overall, these results suggest that this class of ad-
vanced leads shows enhanced potency and cell penetra-
tion, leading to loss of specificity in tissues such as liver
and kidney, where the compound accumulated. However,
these compounds were able to selectively inhibit target
cathepsins within less accessible tissue such as the
RIP1-Tag2 tumors.
Since we were unable to determine the selectivity of our
compounds toward several cysteine cathepsins (i.e., ca-
thepsins K, S, V, F) as a result of their low or nonexistent
expression levels in the tissues used in this study, we de-
cided to test all of the leads against recombinant human
cathepsins V and L (Figure S1). As expected, at the rela-
tively high concentration of 1 mM the broad-spectrum in-
hibitors (AMS7, AMS28) were effective inhibitors of both
enzymes. Similarly, the compounds that showed cathep-
sin B and cathepsin X selectivity in vivo (AMS30, AMS36)
were also somewhat potent inhibitors of cathepsins V and
L. In addition, AMS17, which showed cathepsin B selec-
tivity in rat liver extracts, was quite potent against both ca-
thepsins V and L, while AMS1 and AMS5 were relatively in-
effective inhibitors of these targets. Overall, these results
suggest that our optimal compounds may show some
crossreactivity with other cysteine cathepsin targets;
however, this crossreactivity will only be an issue in tis-
sues in which these targets are expressed and in which
the compounds accumulate.
DISCUSSION
The papain fold cysteine proteases are a relatively small
family of enzymes (11 total in the human genome) that
play a surprisingly diverse set of roles in both normal
and disease processes. The critical role for proteases
such as cathepsin K in bone remodeling has made it a hotly
pursued drug target, with several advanced programs
currently entering or already in clinical trials [12]. Thus,
new methods to rapidly profile the in vivo specificity of in-
hibitors of this family of enzymes are of great value. Some
of the most critical parameters that need to be determined
in order to make sense of preclinical and clinical data are
(1) did the drug get access to the target enzyme? and (2)
does the compound retain its specificity in the relevant
disease tissue or cell population? Often these parameters
are difficult to determine, leading, in some cases, to early
termination of discovery programs or late-stage failures of
drugs due to undesired off-target activities. We describe
here the use of small-molecule screens in relevant tissue
extracts to identify lead compounds that can then be eval-
uated for in vivo potency and selectivity within specific tis-
sues. The results from our synthesis, screening, and
in vivo testing suggest that specificity profiles observed
for covalent inhibitors with rapid clearance seem to be re-
tained in tissues after systemic administration. Further-
more, the absolute selectivity of a given compound seems99–511, May 2007 ª2007 Elsevier Ltd All rights reserved 507
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(A–C) In vivo selectivity of AMS17, AMS28, AMS30, and AMS36 was assessed by treatment of normal mice at doses of 50 and 100 mg/kg daily for 2
days. (A) Liver and (B) kidney tissues from control (DMSO vehicle-treated) and inhibitor-treated mice were collected, homogenized, and labeled with
the general probe 125I-DCG-04. Samples were analyzed by SDS-PAGE, followed by autoradiography. AMS36 was injected in high-DMSO concen-
trations and could only be administered for 1 day. (C) RIP1-Tag2 mice at 13 weeks of age were injected with AMS28, AMS30, and AMS36 at doses of
50 and 100 mg/kg as in (A) and (B). Tumor tissues from control and treated animals were removed and analyzed for residual cathepsin activity as in (A)
and (B). AMS28 showed significant toxicity in these animals at the higher dose of 100 mg/kg, and the study had to be discontinued at this dose. Thus,
only data from the 50 mg/kg dose are shown.to be controlled by its ability to access specific cellular
locations. Thus, these data highlight the need to use highly
sensitive methods such as activity-based profiling to de-
termine key in vivo specificity parameters in order to eval-
uate and select new drug leads for advancement into
human clinical trials.
Motivated by our initial, promising results for the parent
compound JPM-OEt in the RIP1-Tag2 mouse model of
pancreatic cancer [18], we set out to identify a series of
lead compounds with diverse specificity and biodistribu-
tion patterns for further evaluation in this cancer model.508 Chemistry & Biology 14, 499–511, May 2007 ª2007 ElseviWe have chosen to use a competition-based screen
with the ABP 125I-DCG-04 since it allows us to screen rel-
atively small libraries of compounds in a complex pro-
teome that contains multiple active cathepsin targets.
Thus, by using this method we do not need to obtain sig-
nificant quantities of purified recombinant cathepsins, and
we select for compounds that perform well in the context
of the complex cellular environment. In the past, we have
used this method to screen libraries against targets for
which no recombinant source of enzyme was available
[22, 25]. In this study, we demonstrate that an additionaler Ltd All rights reserved
Chemistry & Biology
Selective Inhibitors of Cysteine Cathepsinsbenefit of carrying out initial screens with this method is
the overall high degree of correlation of specificities and
potencies with results obtained in vivo. Thus, we believe
that this method has significant value for use in early
drug development when a focused lead series is identified
and small follow-on libraries of compounds are generated
through medicinal chemistry efforts. In addition, while our
study makes use of covalent inhibitors, the use of this
screening method has been reported for classes of re-
versible inhibitors as well [26].
We found it somewhat surprising that our covalent in-
hibitors were generally able to retain their selectivity
in vivo since we assumed that over time they would pro-
ductively inhibit all targets as a result of the irreversible na-
ture of their inhibition mechanism. In general, we observed
a pattern in which selectivity was controlled by the access
of the compound to the target proteases. In the liver, com-
pounds accumulated, and specificity was only retained for
compounds that had poor overall cellular uptake, while
compounds that showed significant cellular permeability
lost all selectivity. The kidney, while also involved in the fil-
tering of small molecules from the blood, in general accu-
mulated these molecules to a lesser extent than the liver.
As a result, many of the non-cell-permeable compounds
were not able to block intracellular pools of cathepsins.
The RIP1-Tag2 tumors in the pancreas represent the rele-
vant disease tissue in which inhibition of target cathepsins
is desired. We observed potent and selective activity of
compounds in tumor tissues, most likely due to the re-
duced delivery of the compounds to these tissues. Thus,
compounds that are able to selectively and efficiently
knock down cathepsin activities in tumor tissues are
most likely going to induce broad-spectrum inhibition of
cathepsin targets in other major organs such as the liver.
It should be pointed out that the relevant pool of active
cathepsins that may be critical for disease pathogenesis
may differ for each disease state. In the case of the
RIP1-Tag2 model, we have observed therapeutic effects
with compounds that do not readily penetrate cells
(J.A.J. and M.B., unpublished data), suggesting that ex-
tracellular cathepsins secreted by both tumor cells and
cells of the local microenvironment may be the critical
pool to target with small-molecule inhibitors. This extra-
cellular pool likely represents a small fraction of the total
pool of active cathepsins inside the cell and thus could
be effectively blocked without showing any significant
drop in the total amount of active cathepsins, as mea-
sured in tissues extracts by using an ABP. In addition,
compounds that show short half-lives in serum, but that
permanently inhibit their targets and have reduced access
to intracellular targets, may provide maximal efficacy with
minimal toxicity. For this reason, we plan to use several of
the compounds reported in this study for extended drug
trials in the RIP1-Tag2 mice in the near future. These
studies will help to correlate efficacy against the disease
with inhibition and specificity of the lead compounds. In
addition, these studies will help to further define the
correlation of cell permeability and target inhibition with
observed toxicity.Chemistry & Biology 14,SIGNIFICANCE
The processes of compound screening, lead optimi-
zation, and preclinical evaluation are time consuming
and expensive parts of the drug discovery process. In
most cases, compound libraries are screened in vitro
against a purified target that has been validated by
basic biological and pharmacological studies. Only af-
ter extensive in vitro screening is a lead series identi-
fied for advancement into optimization and eventual
testing in vivo. Often compounds are advanced into
preclinical testing in animalmodels and even into early
human clinical trials with only a limited understanding
of in vivo potency and target selectivity in specific tis-
sues and cell populations. We report here the synthe-
sis and screening of several small and focused librar-
ies of epoxysuccinyl-based inhibitors in the CA family
of cysteine proteases. These libraries were used to
identify compounds that showed interesting potency
and selectivity in crude tissue extracts that could
then be rapidly evaluated in vivo by using an activity-
based profiling method. This in vivo profiling method
allowed us tomonitor the extent of targetmodification
in different tissues and provided a direct readout of the
overall specificity of compounds in a specific tissue
of interest. Our results suggest that this class of
compounds shows overall rapid clearance in serum,
resulting in specificity profiles that are controlled
by access of compounds to a given tissue or cell
population. While we have by no means developed
compounds with absolute specificity for any single
cathepsin target, these results have highlighted a
number of important specificity determinants on the
epoxysuccinyl scaffold. In addition, this work has
identified several valuable lead compounds that can
be used to assess the importance of potency, cell per-
meability, and target selectivity of therapeutic agents
designed to target clan CA proteases.
EXPERIMENTAL PROCEDURES
General Methods
Unless otherwise noted, all resins and reagents were purchased from
commercial suppliers and used without further purification. All solvents
used were of HPLC grade. Reverse-phase HPLC was conducted on
a C18 column by using an A¨KTA explorer 100 (Amersham Pharmacia
Biotech). LCMS data were acquired using an API 150EX LC/MS sys-
tem (Applied Biosystems).
General Solid-Phase Synthesis Method
Solid-phase synthesis of all compounds was carried out using
methods recently reported by our group [9, 24]. Solid-phase reactions
were conducted in polypropylene cartridges (Applied Separations, Al-
lentown, PA) with 3-Way Nylon Stopcocks (BioRad Laboratories, Her-
cules, CA). The cartridges were connected to a 20 port vacuum mani-
fold (Waters, Milford, MA) that was used to drain solvent and reagents
from the cartridge. The resin was gently shaken on a rotating shaker
during solid-phase reactions.
Inhibitor Evaluation
Rat liver homogenate (20 ml; 1 mg/ml) in reaction buffer (50 mM sodium
acetate, 2 mM DTT, 5 mM MgCl2 [pH 5.5]) was incubated for 30 min499–511, May 2007 ª2007 Elsevier Ltd All rights reserved 509
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04 (106 cpm in 1 ml) was added, and the samples were incubated for
1 hr. Samples were quenched by the addition of 43 SD sample buffer,
and samples were boiled for 5 min. Proteins were resolved by SDS-
PAGE, and the labeled cathepsin activities were visualized by autora-
diography by using a Typhoon 9410 imager (Amersham Biosciences).
Densitometry was performed by using NIH-Image software. Numerical
values for percent inhibitions were determined and converted to heat
maps by using the programs Tree View and Cluster, written by Mike
Eisen (http://rana.lbl.gov/EisenSoftware.htm), as reported previously
[22]. Established numerical values for percent inhibitions were applied
by using GraphPad Prism 4 software to determine the observed IC50
values, as given in Figure 4B.
In Vivo Inhibitor Treatment
Each of the AMS inhibitors was dissolved in a solution of DMSO/H2O.
Control C57BL/6 mice and RIP1-Tag2 mice [30] at 13 weeks of age
were treated twice daily with an IP injection of each inhibitor or vehicle
control (DMSO/H2O) at doses of 50 mg/kg/day or 100 mg/kg/day for 2–
7 days. The final inhibitor dose was administered 1 hr prior to sacrifice.
Mice were then anesthetized with an IP injection of 2.5% avertin and
were heart perfused with PBS. All organs were collected immediately
and frozen in liquid nitrogen. Organs were weighed and dounced in ly-
sis buffer (50 mM acetate [pH 5.5], 5 mM MgCl2, 250 mM sucrose, and
2 mM DTT) and centrifuged at 14,000 3 g for 20 min at 4C. Protein
concentration of the supernatant was then determined by Bradford as-
say after removal of the pellet. The homogenates were then labeled
and visualized as described above in the inhibitor evaluation section.
Methods for Murine Pharmacokinetics Studies
All murine PK studies were carried out at NCI-Frederick. NCI-Frederick
is accredited by AAALACi and follows the Public Health Service Policy
on the Care and Use of Laboratory Animals. Animal care was provided
in accordance with the procedures outlined in the Guide for Care and
Use of Laboratory Animals (NIH publication No. 86-23, 1985). Young-
adult, male nu/nu Ncr mice (average body weight of 26 g; Animal
Production Program, NCI, Frederick, MD) were used in the PK studies.
Animals were maintained on hardwood chip bedding in temperature-
controlled rooms (20C) with a 12 hr light-dark cycle. Standard diet
(Rat and Mouse 18% Protein Diet, PMI Nutrition International, Inc.,
Brentwood, MO) and water were provided ad libitum. Housing, animal
care, and all experimental procedures and manipulations were carried
out in an AAALACi-accredited facility in strict compliance with the Na-
tional Institutes of Health guidelines for the care and use of laboratory
animals and were approved by the NCI-Frederick Animal Care and Use
Committee.
Pharmacokinetics Studies
Each analog was administered to mice by IV (tail vein) and IP injection,
and by oral gavage (PO) at a dose of 50 mg/kg. Two mice were used for
each route of administration. All analogs were dissolved in DMSO and
given in a dose volume of 1 ml/kg. For each route of administration,
plasma was collected from the retro-orbital sinus of one mouse after
5, 30, and 120 min and from the other mouse after 15, 60, and 90
min. Blood was collected into heparinized microfuge tubes and imme-
diately chilled in an ice bath for 1 min. Samples were then centrifuged
at 13,000 3 g for 3 min in a refrigerated centrifuge (4C), and plasma
was separated, flash frozen, and stored at 70C until assayed.
HPLC-Mass Spectrometry Assay
Samples were prepared for analysis by adding 150 ml ice-cold metha-
nol to 50 ml plasma, followed by vigorous mixing. The mixture was then
centrifuged at 13,000 3 g for 12 min, the supernatant (150 ml) was
removed and mixed with 450 ml 0.1% formic acid, and 580 ml was in-
jected onto the column. Samples were analyzed with an Agilent (Agi-
lent Technologies, Palo Alto, CA) HPLC/MS system, consisting of
1100 Series chromatographic modules interfaced with an ion trap
MS module (model G2445A) controlled through a Windows NT-based510 Chemistry & Biology 14, 499–511, May 2007 ª2007 ElsevChemStation. Chromatography was conducted at ambient tempera-
ture by using a 4.6 3 250 mm I.D. Atlantis C18 column (Waters, Inc.,
Milford, MA), eluted isocratically (flow rates ranging from 0.6 to 0.75
ml/minute) with a mobile phase composed of acetonitrile-0.1% formic
acid (proportions ranging from 15:85, v/v to 25:75, v/v), the precise cir-
cumstances being dependent on the optimal conditions required for
each analog. The column effluent was introduced into the MS module
operated under positive ion electrospray conditions in scanning mode
(100–2200 m/z), and the appropriate mass ion for each analog was ex-
tracted during data analysis. In our hands, we found the ester analogs
to hydrolyze immediately in plasma (data not shown), prompting us to
monitor ions for the corresponding carboxylic acids rather than those
of the parent compounds, for these molecules. Under the conditions
described, retention times of the analogs varied from 8 to 13 min,
and the lower limits of quantification (loq; defined as the lowest con-
centration that could be quantified with acceptable reproducibility
[RSD < 15%]) ranged from 0.1 to 0.8 mM. Calibration curves were con-
structed by plotting the respective peak areas against the known ana-
lyte concentration in plasma standards. Typically, seven to eight stan-
dards covering a concentration range from the loq to 10 mM were
employed. Weighted, linear least-squares regression analysis was
performed to determine the slope and y intercept of the best-fit line.
Analyte concentrations in unknown samples were calculated by inter-
polation from the regression line. Each unknown sample was assayed
in duplicate, and the average of the assayed values was used for data
analysis.
Pharmacokinetic Analysis
The beginning and ending times for the injection and the collection in-
tervals were recorded to the nearest second. Plasma concentration
versus time profiles were constructed by using the plasma concentra-
tion for the individual animal at each time point and the time of collec-
tion. The time of collection was calculated from the beginning of the
administration to the midpoint of the sample-collection interval. Areas
under the curve (AUC) were calculated by ‘‘trapezoidal rule’’ from time
0 to the last time point at which the analog was detected. The biolog-
ical half-life was estimated by nonlinear regression analysis when the
data permitted such analysis. The bioavailable fraction (%F) was cal-
culated by dividing the AUC determined after IP or PO administration
by the AUC determined after IV administration for each analog.
Supplemental Data
Supplemental Data include pharmacokinetic values along with LC-MS
spectra of representative compounds and are available at http://www.
chembiol.com/cgi/content/full/14/5/499/DC1/.
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